急性髓系白血病：新确诊患者从一线诱导到缓解和复发的资源利用和支出的回顾性索赔分析

数据集获取（Figshare）

• 源站标题：Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse
• DOI：10.6084/m9.figshare.4315841.v1
• 发布日期：2016-12-14
• 文件数：2 个
• 文件总体积：92.36 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Acute_myeloid_leukemia_a_retrospective_claims_analysis_of_resource_utilization_and_expenditures_for_newly_diagnosed_patients_from_first-line_induction_to_remission_and_relapse/4315841

命令行下载

curl -L -o "icmo_a_1267615_sm9833.docx" "https://ndownloader.figshare.com/files/7039322"
curl -L -o "icmo_a_1267615_sm2310.pdf" "https://ndownloader.figshare.com/files/7039325"

文件清单

• icmo_a_1267615_sm9833.docx（31.20 KB）
• icmo_a_1267615_sm2310.pdf（61.16 KB）

文件总体积 92.36 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objective: The objective of this study was to estimate resource utilization and expenditures for patients with acute myeloid leukemia (AML) in a real-world claims database.
Research design and methods: AML patients were identified in MarketScan claims databases between 1 January 2009 and 31 January 2015. Patients had a minimum of two AML diagnosis codes, hospitalization within 14 days after initial diagnosis, and ≥6 months of enrollment before initial diagnosis. Patients were monitored from first-line induction to a record of remission. A subset had a record of a second treatment period, defined as time from relapse to remission. Patient demographics, AML risk factors, and comorbidities were recorded. Descriptive analysis of utilization and expenditures (in 2014 $US) were reported for each cohort.
Results: The inclusion criteria were met in 1597 patients (mean age, 58.4 years; 51.0% male). Ninety percent of patients had ≥1 risk factor for AML. Mean (SD) healthcare expenditures for patients from first-line induction to remission (n = 681) were $208,857 ($152,090). Of the 157 who had a record of relapse, 70 had a record of a second remission. Expenditures for these patients (n = 70) from relapse to remission were $142,569 ($208,307); 60% were admitted to a hospital for a mean of 18.5 hospital days, and 20% had ≥1 emergency room visit.
Conclusions: Although this claims-based analysis is limited by a lack of generalizability to noninsured populations and potential underreporting of certain events and diagnoses, we found that treating AML patients poses a significant healthcare burden, during both first-line induction and relapse. With people living longer, the number of cases of AML is expected to increase in the future.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.4315841.v1（source: https://tandf.figshare.com/articles/dataset/Acute_myeloid_leukemia_a_retrospective_claims_analysis_of_resource_utilization_and_expenditures_for_newly_diagnosed_patients_from_first-line_induction_to_remission_and_relapse/4315841）。